RxDoctor Payments Data

Sharon Boyce, MD

Family Medicine · Tucson, AZNPI 1053508838

Payments from drug & device makers

$757in general payments, 2019–2025

Across 46 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$125
  • Novo Nordisk$122
  • Sanofi-aventis U.S. LLC$86
  • Pfizer$66
  • Corcept Therapeutics$66
  • AstraZeneca$62
  • plus $231 from 7 others

What the payments were for

  • Food & beverage$757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757 in reported general payments places this provider in the 65th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$36,758
Medicare patients
154
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$47,609
OzempicSemaglutide27$41,376
JardianceEmpagliflozin26$27,041
TrulicityDulaglutide18$20,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,934
Tresiba Flextouch U-100Insulin Degludec11$12,954
Breo ElliptaFluticasone/Vilanterol12$10,060
SymbicortBudesonide/Formoterol Fumarate23$6,539
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$5,193
Albuterol Sulfate HfaAlbuterol Sulfate93$5,126
Gabapentin153$3,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,032
Levothyroxine Sodium301$2,358
Atorvastatin Calcium339$1,940
Omeprazole158$1,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$47,60931 claims
Novo NordiskOzempic$122$41,37627 claims
Boehringer IngelheimJardiance$16$27,04126 claims
Lilly USA, LLCTrulicity$15$20,35918 claims
AstraZenecaSymbicort$62$6,53923 claims
AbbVieSynthroid$125$1,12927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →